Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients

Publish date:: June 16, 2020

Key clinical point: Dapagliflozin treatment of patients with heart failure with reduced ejection fraction slowed incident type 2 diabetes.

Major finding: During a median 18 months of follow-up, incident type 2 diabetes occurred in 4.9% of dapagliflozin-treated patients and 7.1% of controls.

Study details: A prespecified, exploratory analysis of data from DAPA-HF, a multicenter randomized trial with 2,605 patients without diabetes at entry.

Disclosures: DAPA-HF was sponsored by AstraZeneca, the company that markets dapagliflozin (Farxiga). Dr. Inzucchi has been a consultant to AstraZeneca and also to Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Sanofi/Lexicon, and vTv Therapeutics. Dr. Vaduganathan has been an adviser to AstraZeneca and to Amgen, Baxter, Bayer, Boehringer Ingelheim, Cytokinetics, and Relypsa.

Citation:

Inzucchi SE et al. ADA 2020, Abstract 271-OR.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Annual WCC visits significantly limit asthma worsening,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

Must Reads in Cardiology

Sac/val heart failure benefit extends to diabetes patients,

Sedentary postmenopausal women have higher heart failure risk,

Experts disagree with USPSTF’s take on pediatric blood pressure screening,

GALACTIC-HF: New ‘myotropic’ drug class shows modest HFrEF benefit,

Don’t miss cardiovascular risk factors in transgender patients,